Bicycle Therapeutics plc Income (Loss) from Continuing Operations before Income Taxes, Domestic
Bicycle Therapeutics plc (BCYC) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$225.46 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-17
- Bicycle Therapeutics plc income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$225.46M.
- Bicycle Therapeutics plc income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$179.61M.
- Bicycle Therapeutics plc income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$182.98M, a 9096.07% decline from fiscal 2022.
- Bicycle Therapeutics plc income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was $2.03M, a 91.17% increase from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$225.46M 10-K · filed 2026-03-17 | |
| 2024-12-31 | -$179.61M 10-K · filed 2026-03-17 | $5.81M 10-K · filed 2025-02-25 |
| 2023-12-31 | -$182.98M 10-K · filed 2026-03-17 | $3.77M 10-K · filed 2024-02-20 |
| 2022-12-31 | $2.03M 10-K · filed 2025-02-25 | |
| 2021-12-31 | $1.06M 10-K · filed 2024-02-20 | |
| 2020-12-31 | $787.00K 10-K · filed 2023-02-28 | |
| 2019-12-31 | $1.04M 10-K · filed 2022-03-01 | |
| 2018-12-31 | -$13.00K 10-K · filed 2021-03-11 | |
| 2017-12-31 | $37.00K 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |